Labcorp backed a debt and equity round for the cancer diagnostics technology developer as it advances its screening platform torwards commercialisation.
Geneoscopy, a US-based developer of colorectal cancer diagnostics technology, has secured $105m in a series B equity and debt round featuring clinical laboratory network Labcorp.
Lightchain Capital and NT Investments co-led the round and were also joined by Morningside Ventures, Cultivation Capital, Innovatus Capital Partners and BioGenerator Ventures.
Founded in 2015, Geneoscopy is developing technology that analyses RNA from patient stool samples to detect pre-cancerous lesions. It was granted a breakthrough device designation from the US Food and Drug Administration…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
